Last reviewed · How we verify
Feru-guard 100M — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
Feru-guard 100M (Feru-guard 100M) — Glovia Co., Ltd.. Feru-guard 100M is believed to provide antioxidant and anti-inflammatory effects through ferulic acid and related compounds.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Feru-guard 100M TARGET | Feru-guard 100M | Glovia Co., Ltd. | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Feru-guard 100M CI watch — RSS
- Feru-guard 100M CI watch — Atom
- Feru-guard 100M CI watch — JSON
- Feru-guard 100M alone — RSS
Cite this brief
Drug Landscape (2026). Feru-guard 100M — Competitive Intelligence Brief. https://druglandscape.com/ci/feru-guard-100m. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing